1. Besse B, Ropert S, Soria JC. Targeted therpies in lung cancer. Annals Oncol 2007;18:S9. ix135-ix142.
2. Thatcher N. The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer 2007;57:S2. S18-S23.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated in non-small cell lung cancer. N Engl J Med 2005;353:123-132.
4. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F. Primary and aquired resistance to anti-EGFR targetd drugs in cancer therapy. Differentiation 2007;75:788-799.
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-2550.